Cell-permeable peptides can penetrate the cell membrane and become internalized either alone or coupled to other molecules. Their value has been recognized especially in vaccination and gene therapy studies (for a review, see Reference 1). Gratton et al. reported recently about the use of these peptides in enhancement of virusmediated gene delivery in vitro and in vivo (2) . They showed that polybasic peptides derived from Drosophila Antennapedia homeodomain (Antp) or human immunodeficiency virus type 1 (HIV-1) transactivator protein (TAT) improved adenoviral and retroviral transduction in cultured monkey COS-7 cells, bovine aortic endothelial cells, and human umbilical vascular endothelial cells, as well as in mouse arteries, muscle, and skin in vivo when precomplexed with viral vector particles. Based on their results, Gratton et al. (2) suggested that highly positively charged peptides can enhance the transduction by concentrating viral particles to the cell surface and by improving receptor-dependent uptake mechanisms.
Insufficient transduction efficiency is still considered the major problem in gene therapy research. Because high gene transfer rate is particularly important in most cancer gene therapy approaches and Gratton et al. (2) did not test their concept in human tumor cells, we conducted a series of experiments to verify the utility of cell-permeable peptide-complexed virus vectors in cancer gene therapy. In addition to the Antp peptide (RQIKIWFQNRRMKWKK), we used two versions of the HIV-1 TAT peptide: TAT1 (YGRKKRRQRRR, used in most earlier studies) (1) and TAT2 (GRKKRRQRRRPPQ, presumably used by Gratton et al.) (2) . Furthermore, two polycationic compounds, polybrene (hexadimethrine bromide) and protamine sulfate, were used to identify the contribution of a plain electrostatic effect (i.e., the reduction of the electrostatic repulsion between negatively charged viral particles and cell membranes). Polybrene has been known to enhance retroviral infection since the late 1960s (3). It is nowadays a commonly used enhancer of retroviral transduction, and its mechanism of action (4, 5) and positive effect to adenoviral gene transfer (6) have been elucidated. Protamine sulfate has been designated as a more clinically relevant alternative for polybrene in retroviral gene therapy (7) , and its utility in adenoviral gene transfer has been acknowledged (8) .
The cell-penetrating peptides were incubated with a serotype 5, E1/E3-deleted adenovirus vector AdTK-GFP (9) and a second generation VSV-G pseudotyped lentivirus vector WOX-TK-GFP (10) as described in the original report (2) . Polybrene (8 μg/ mL) and protamine sulfate (5 μg/mL) were added to virus dilutions, and the resulting complexes were then used for transduction of one monkey kidney fibroblast cell line (COS-7) and four different human cancer cell lines representing ovarian carcinoma (SKOV3. ip1, HEY), prostate carcinoma (PC-3), and osteosarcoma (MG-63). The human tumor cell lines were selected due to their known features as targets for viral gene transfer. All of these cell lines were moderate or poor targets for lentiviral and/or adenoviral vectors (9, 11) , and transduction of these cells would apparently benefit from peptide-mediated enhancement. The results, indicated as proportion of green fluorescent protein (GFP) positive cells, were determined by flow cytometry, and a one-way analysis of variance with Dunnett's post hoc test for multiple comparisons was used for statistical analysis.
To verify the results obtained by Gratton 
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cells by flow cytometry 2 days (adenovirus) or 4 days (lentivirus) posttransduction confirmed that the Antp peptide can significantly improve adenoviral and lentiviral gene transfer (P < 0.001). However, this effect was not as impressive as observed earlier (2) (i.e., from 10% with adenovirus vector alone to almost 95% when complexed with the Antp peptide). In our experiments, the Antp peptide doubled the gene transfer efficiency of both vector types, and a similar effect was obtained with the TAT-derived peptides. Interestingly, polybrene and protamine were able to boost the gene delivery with both vector types equally well (protamine) or even better (polybrene) than any of the peptides. It is difficult to determine, why Gratton and colleagues obtained higher enhancement of adenoviral gene delivery with Antp peptide even though their peptide concentration was similar to that used in our experiment. It is possible that the COS-7 cell populations in two different laboratories may not be completely identical or the quality of the adenovirus and peptide preparations may play a role. Furthermore, there may be minor differences in the complex formation or transduction protocols, resulting in variation in the peptide-mediated enhancement. Taken together, our results with COS-7 cells confirm the enhancement observed by Gratton et al. (2), but also point out that depending on the conditions and materials used, the degree of gene delivery enhancement is likely to vary from laboratory to laboratory. To test the utility of peptide-mediated enhancement in human tumor cell lines, SKOV3.ip1, HEY, PC-3, and MG-63 cells were transduced identically as COS-7 cells. As shown in Figure 2 , all the peptides and polycations were able to boost viral gene delivery into human tumor cells similarly as shown with COS-7 monkey fibroblasts. The results regarding the tumor cell lines can be summarized as follows: (i) peptides enhanced significantly both lentiviral and adenoviral gene transfer (P < 0.001), and in all cases the order of enhancement was Antp ≥ TAT1 > TAT2; (ii) peptides could not significantly improve the poor lentiviral transduction of MG-63 cells; (iii) polycations were efficient transduction enhancers with both vector types (P < 0.001), except in two cases (lentivirus complexed with protamine sulfate, in PC-3 and MG-63 cells); and (iv) polybrene turned out to be a better enhancer than any of the peptides, and in most cases the protamine sulfate effect was also comparable to that of the best peptides. Figure 1 were used. ***, P < 0.001, and *, P < 0.05 as compared with the control group (transduction with no additive compounds). GFP, green fluorescent protein; TAT1 and TAT2, two human immunodeficiency virus type 1 (HIV-1) TAT-derived peptides; Antp, Drosophila Antennapedia homeodomain-derived peptide.
Taken together, our results demonstrate that the transduction rate of adenovirus and lentivirus vectors can be significantly boosted with TAT and Antp cell permeable peptides, but similar or better results can be obtained with commonly used polycations. The effect of each peptide or polycation turned out to be surprisingly similar in all the studied cell lines, suggesting that the effect was due to simple electrostatic interactions and was not dependent on, for example, the protein composition of the target cell plasma membrane. However, the enhancing effect appeared to be dependent on the peptide sequence; TAT1 and TAT2 peptides displayed different degrees of enhancement, especially with adenovirus vector, although their net charges were identical. In our studies, we used only one peptide concentration (0.5 mM) that was also chosen by the authors of the original paper (2) . It can be speculated that this peptide concentration was already toxic, and lower concentrations could have yielded better results. This was not the case however, since we observed practically no enhancement of gene transfer with 0.1 mM peptide concentration (results not shown). Furthermore, 0.5 mM peptides did not induce any notable cytotoxicity in any of the cell lines (as judged by microscopical examination 48 h posttransduction, results not shown). Higher than 0.5 mM concentrations could theoretically improve the effect, but these concentrations would become very expensive, especially when compared with the polycations. The cost per transduction with the peptides is approximately 500 times higher than with polybrene and protamine (as determined on the basis of prices in Finland in 2005). Even though polybrene yielded better enhancement than protamine sulfate, one has to bear in mind that polybrene may have toxic side effects, and it is not a clinically approved molecule. Thus, considering the in vitro results presented in this report, the clinical utility of the tested molecules and their costs, it is apparent that protamine sulfate has the best risk/benefit ratio compared with any of the peptides or polybrene. 
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